Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Netscientific Appoints Ian Postlethwaite as CFO

5 Apr 2016 07:00

RNS Number : 1367U
NetScientific PLC
05 April 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

 

London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

 

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

 

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

 

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

 

 

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

 

Allergy Therapeutics Italia s.r.l.

 

Allergy Therapeutics Iberia S.L.

 

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

 

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALFFEISRISIIR
Date   Source Headline
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.